The urgency of Marburg therapeutics: preventing local outbreaks from the potential global spread.

This article discusses the urgent need for therapeutics to prevent local outbreaks of the Marburg virus from potentially spreading globally. The Marburg virus is a highly pathogenic virus that causes severe hemorrhagic fever in humans and nonhuman primates. Currently, there are no approved therapeutics for Marburg virus disease (MVD), highlighting the need for extensive research. Various potential treatments, including antiviral drugs and vaccines, are being explored, but further research is needed to develop effective countermeasures against MVD. The article emphasizes the importance of investing in research and innovation to address the challenges posed by emerging infectious diseases like Marburg. The text discusses the development of vaccines and therapeutics for Marburg virus disease (MVD). Several vaccine candidates are currently undergoing clinical trials, including one that combines Marburg and Ebola virus antigens. However, none of the vaccine candidates have reached advanced clinical trial stages yet. The text emphasizes the need for collaborative research efforts and standardized approaches to address the public health threat posed by Marburg virus. It also highlights the challenges of diagnosing and handling the virus due to its high pathogenicity and the need for Biosafety Level 4 containment. The natural reservoir of Marburg virus is the Egyptian fruit bat, and pigs can act as intermediate hosts. The text calls for a multipronged approach to prevent future MVD outbreaks, including strengthening public health infrastructure, conducting research on diagnostics and therapeutics, and raising awareness among the public and healthcare workers. The text acknowledges the [Extracted from the article]